DPC-423 is a biphenylamine-containing amide which is under development by Bristol-Myers Squibb (formerly DuPont Pharmaceuticals) as a Factor Xa inhibitor for the potential treatment of thrombotic disorders [372092]. As of August 2000, DPC-423 was in phase I trials [380880]. DPC-423 was discovered as a result of SAR modifications of DuPont's SN-429, including replacement of the benzamidine moiety with a less basic benzylamine [398701]. Its 2-aminomethylphenyl analog DPC-602 is also under investigation for thrombotic disorders [402714].
DPC-423 Bristol-Myers Squibb / Taglialatela, Maurizio. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - 3:2(2002), p. 252-4.
DPC-423 Bristol-Myers Squibb
TAGLIALATELA, MAURIZIO
2002
Abstract
DPC-423 is a biphenylamine-containing amide which is under development by Bristol-Myers Squibb (formerly DuPont Pharmaceuticals) as a Factor Xa inhibitor for the potential treatment of thrombotic disorders [372092]. As of August 2000, DPC-423 was in phase I trials [380880]. DPC-423 was discovered as a result of SAR modifications of DuPont's SN-429, including replacement of the benzamidine moiety with a less basic benzylamine [398701]. Its 2-aminomethylphenyl analog DPC-602 is also under investigation for thrombotic disorders [402714].I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.